modelDiazoxide
Extends from Pharmacolibrary.Drugs.ATC.C.C02DA01.
Information
| name: | Diazoxide | |
| ATC code: | C02DA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 0.3 | L |
| clearance: | 3.0 | ml/min/kg |
| other parameters in model implementation | ||
Diazoxide is a potassium channel activator used as a vasodilator in the treatment of acute hypertension and hypertensive emergencies. It is also used to manage hypoglycemia due to hyperinsulinism. Diazoxide is an approved drug but less commonly used today due to the availability of newer antihypertensive agents.
Pharmacokinetics
Pharmacokinetics reported in healthy adult volunteers, both sexes. Orally administered. Typical therapeutic dosing.
References
Kizu, R, et al., & Hasegawa, T (2017). Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia. Hormone research in paediatrics 88(5) 316–323. DOI:10.1159/000478696 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28715810
Ford, JL, et al., & Gonzalez, D (2022). Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity. Journal of clinical pharmacology 62(8) 960–969. DOI:10.1002/jcph.2034 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35119103
Little, GL, & Boniface, KS (2005). Are one or two dangerous? Sulfonylurea exposure in toddlers. The Journal of emergency medicine 28(3) 305–310. DOI:10.1016/j.jemermed.2004.09.012 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15769574
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)